O	0	14	Colorimetrical	Colorimetrical	JJ	B-NP
O	15	19	rate	rate	NN	I-NP
O	20	25	assay	assay	NN	I-NP
O	26	29	for	for	IN	B-PP
B-Organism_substance	30	37	urinary	urinary	JJ	B-NP
O	38	48	dipeptidyl	dipeptidyl	NN	I-NP
O	49	58	peptidase	peptidase	NN	I-NP
O	59	61	IV	IV	CD	I-NP
O	62	63	(	(	(	O
O	63	68	DPPIV	DPPIV	NN	B-NP
O	68	69	)	)	)	O
O	70	78	activity	activity	NN	B-NP
O	79	84	using	use	VBG	B-VP
O	85	86	a	a	DT	B-NP
O	87	90	new	new	JJ	I-NP
O	91	100	substrate	substrate	NN	I-NP
O	100	101	.	.	.	O

O	102	104	We	We	PRP	B-NP
O	105	116	synthesized	synthesize	VBD	B-VP
O	117	118	a	a	DT	B-NP
O	119	122	new	new	JJ	I-NP
O	123	132	substrate	substrate	NN	I-NP
O	133	139	glycyl	glycyl	NN	I-NP
O	139	140	-	-	HYPH	B-NP
O	140	141	L	L	NN	I-NP
O	141	142	-	-	HYPH	B-NP
O	142	149	proline	proline	NN	I-NP
O	150	151	3	3	CD	I-NP
O	151	152	,	,	,	I-NP
O	152	153	5	5	CD	I-NP
O	153	154	-	-	HYPH	O
O	154	161	dibromo	dibromo	AFX	O
O	161	162	-	-	HYPH	B-NP
O	162	163	4	4	CD	I-NP
O	163	164	-	-	HYPH	I-NP
O	164	178	hydroxyanilide	hydroxyanilide	NN	I-NP
O	179	180	(	(	(	O
O	180	183	Gly	Gly	NN	B-NP
O	183	184	-	-	HYPH	B-NP
O	184	187	Pro	Pro	NN	I-NP
O	187	188	-	-	HYPH	B-NP
O	188	192	DBAP	DBAP	NN	I-NP
O	192	193	)	)	)	O
O	193	194	,	,	,	O
O	195	198	for	for	IN	B-PP
O	199	209	dipeptidyl	dipeptidyl	NN	B-NP
O	210	219	peptidase	peptidase	NN	I-NP
O	220	222	IV	IV	CD	I-NP
O	223	224	(	(	(	O
O	224	229	DPPIV	DPPIV	NN	B-NP
O	229	230	)	)	)	O
O	230	231	.	.	.	O

O	232	235	Its	Its	PRP$	B-NP
O	236	246	hydrolysis	hydrolysis	NN	I-NP
O	247	249	by	by	IN	B-PP
O	250	255	DPPIV	DPPIV	NN	B-NP
O	256	264	resulted	result	VBD	B-VP
O	265	267	in	in	IN	B-PP
O	268	271	the	the	DT	B-NP
O	272	281	formation	formation	NN	I-NP
O	282	284	of	of	IN	B-PP
O	285	286	a	a	DT	B-NP
O	287	298	chromophore	chromophore	NN	I-NP
O	298	299	,	,	,	O
O	300	301	2	2	CD	B-NP
O	301	302	,	,	,	I-NP
O	302	303	6	6	CD	I-NP
O	303	304	-	-	HYPH	I-NP
O	304	317	dibromophenol	dibromophenol	NN	I-NP
O	317	318	-	-	HYPH	I-NP
O	318	322	indo	indo	AFX	B-NP
O	322	323	-	-	HYPH	B-NP
O	323	324	p	p	NN	I-NP
O	324	325	-	-	HYPH	I-NP
O	325	332	xylenol	xylenol	NN	I-NP
O	332	333	,	,	,	O
O	334	337	and	and	CC	O
O	338	341	its	its	PRP$	B-NP
O	342	349	maximal	maximal	JJ	I-NP
O	350	360	absorption	absorption	NN	I-NP
O	361	371	wavelength	wavelength	NN	I-NP
O	372	373	(	(	(	O
O	373	376	600	600	CD	B-NP
O	377	379	nm	nm	NN	I-NP
O	379	380	)	)	)	O
O	381	384	was	be	VBD	B-VP
O	385	391	longer	long	JJR	B-ADJP
O	392	396	than	than	IN	B-PP
O	397	401	that	that	DT	B-NP
O	402	404	of	of	IN	B-PP
O	405	406	p	p	NN	B-NP
O	406	407	-	-	HYPH	B-NP
O	407	419	nitroaniline	nitroaniline	NN	I-NP
O	420	421	(	(	(	O
O	421	424	415	415	CD	B-NP
O	425	427	nm	nm	NN	I-NP
O	427	428	)	)	)	O
O	429	437	released	release	VBN	B-VP
O	438	442	from	from	IN	B-PP
O	443	455	conventional	conventional	JJ	B-NP
O	456	465	substrate	substrate	NN	I-NP
O	465	466	,	,	,	O
O	467	473	glycyl	glycyl	NN	B-NP
O	473	474	-	-	HYPH	B-NP
O	474	475	L	L	NN	I-NP
O	475	476	-	-	HYPH	O
O	476	483	proline	proline	NN	B-NP
O	484	485	p	p	NN	I-NP
O	485	486	-	-	HYPH	B-NP
O	486	498	nitroanilide	nitroanilide	NN	I-NP
O	499	500	(	(	(	O
O	500	503	Gly	Gly	NN	B-NP
O	503	504	-	-	HYPH	B-NP
O	504	507	Pro	Pro	NN	I-NP
O	507	508	-	-	HYPH	B-NP
O	508	511	pNA	pNA	NN	I-NP
O	511	512	)	)	)	O
O	512	513	.	.	.	O

O	514	516	We	We	PRP	B-NP
O	517	521	also	also	RB	B-ADVP
O	522	533	established	establish	VBD	B-VP
O	534	537	the	the	DT	B-NP
O	538	542	rate	rate	NN	I-NP
O	543	548	assay	assay	NN	I-NP
O	549	552	for	for	IN	B-PP
B-Organism_substance	553	560	urinary	urinary	JJ	B-NP
O	561	566	DPPIV	DPPIV	NN	I-NP
O	567	575	activity	activity	NN	I-NP
O	576	581	using	use	VBG	B-VP
O	582	585	Gly	Gly	NN	B-NP
O	585	586	-	-	HYPH	B-NP
O	586	589	Pro	Pro	NN	I-NP
O	589	590	-	-	HYPH	I-NP
O	590	594	DBAP	DBAP	NN	I-NP
O	594	595	.	.	.	O

O	596	599	The	The	DT	B-NP
O	600	607	optimum	optimum	JJ	I-NP
O	608	610	pH	pH	NN	I-NP
O	611	614	was	be	VBD	B-VP
O	615	622	between	between	IN	B-PP
O	623	624	8	8	CD	B-NP
O	624	625	.	.	.	O
O	625	626	5	5	CD	B-NP
O	627	630	and	and	CC	I-NP
O	631	632	9	9	CD	I-NP
O	632	633	.	.	.	I-NP
O	633	634	0	0	CD	I-NP
O	634	635	.	.	.	O

O	636	639	The	The	DT	B-NP
O	640	648	apparent	apparent	JJ	I-NP
O	649	651	Km	Km	NN	I-NP
O	652	655	was	be	VBD	B-VP
O	656	657	1	1	CD	B-NP
O	657	658	.	.	.	O
O	658	659	1	1	CD	B-NP
O	660	664	mmol	mmol	NN	I-NP
O	664	665	/	/	SYM	B-NP
O	665	666	1	1	CD	I-NP
O	666	667	.	.	.	O

O	668	671	The	The	DT	B-NP
O	672	682	detectable	detectable	JJ	I-NP
O	683	688	range	range	NN	I-NP
O	689	692	was	be	VBD	B-VP
O	693	694	2	2	CD	B-NP
O	694	695	.	.	SYM	I-NP
O	695	696	5	5	CD	I-NP
O	696	697	-	-	HYPH	I-NP
O	697	700	350	350	CD	I-NP
O	701	702	U	U	NN	I-NP
O	702	703	/	/	SYM	B-NP
O	703	704	l	l	NN	I-NP
O	704	705	.	.	.	O

O	706	708	No	No	DT	B-NP
O	709	716	changes	change	NNS	I-NP
O	717	719	in	in	IN	B-PP
O	720	725	blank	blank	JJ	B-NP
O	726	732	values	value	NNS	I-NP
O	733	741	occurred	occur	VBD	B-VP
O	742	752	throughout	throughout	IN	B-PP
O	753	756	the	the	DT	B-NP
O	757	763	enzyme	enzyme	NN	I-NP
O	764	772	reaction	reaction	NN	I-NP
O	773	775	in	in	IN	B-PP
O	776	779	the	the	DT	B-NP
O	780	787	optimum	optimum	JJ	I-NP
O	788	790	pH	pH	NN	I-NP
O	790	791	.	.	.	O

O	792	795	Its	Its	PRP$	B-NP
O	796	801	value	value	NN	I-NP
O	802	805	was	be	VBD	B-VP
O	806	810	also	also	RB	B-ADVP
O	811	815	much	much	RB	B-ADJP
O	816	821	lower	low	JJR	I-ADJP
O	822	826	than	than	IN	B-PP
O	827	830	Gly	Gly	NN	B-NP
O	830	831	-	-	HYPH	B-NP
O	831	834	Pro	Pro	NN	I-NP
O	834	835	-	-	HYPH	B-NP
O	835	838	pNA	pNA	NN	I-NP
O	838	839	.	.	.	O

O	840	843	CVs	CV	NNS	B-NP
O	844	847	for	for	IN	B-PP
O	848	854	within	within	IN	B-PP
O	854	855	-	-	HYPH	B-NP
O	855	858	run	run	VBN	B-VP
O	859	862	and	and	CC	O
O	863	870	between	between	IN	B-PP
O	870	871	-	-	HYPH	B-NP
O	871	874	run	run	VBN	B-VP
O	875	879	were	be	VBD	B-VP
O	880	881	1	1	CD	B-NP
O	881	882	.	.	.	O
O	882	883	1	1	CD	B-NP
O	883	884	%	%	NN	I-NP
O	885	886	(	(	(	O
O	886	887	n	n	NN	B-NP
O	888	889	=	=	SYM	B-VP
O	890	892	10	10	CD	B-NP
O	892	893	)	)	)	O
O	894	897	and	and	CC	O
O	898	899	3	3	CD	B-NP
O	899	900	.	.	.	O
O	900	901	0	0	CD	B-NP
O	901	902	%	%	NN	I-NP
O	903	904	(	(	(	O
O	904	905	n	n	NN	B-NP
O	906	907	=	=	SYM	B-VP
O	908	910	10	10	CD	B-NP
O	910	911	)	)	)	O
O	911	912	,	,	,	O
O	913	925	respectively	respectively	RB	B-ADVP
O	925	926	.	.	.	O

O	927	932	Among	Among	IN	B-PP
O	933	939	tested	test	VBN	B-NP
O	940	950	peptidases	peptidase	NNS	I-NP
O	950	951	,	,	,	O
O	952	956	only	only	RB	B-NP
O	957	962	DPPIV	DPPIV	NN	I-NP
O	963	968	could	could	MD	B-VP
O	969	978	hydrolyze	hydrolyze	VB	I-VP
O	979	982	Gly	Gly	NN	B-NP
O	982	983	-	-	HYPH	B-NP
O	983	986	Pro	Pro	NN	I-NP
O	986	987	-	-	HYPH	I-NP
O	987	991	DBAP	DBAP	NN	I-NP
O	991	992	.	.	.	O

O	993	998	Among	Among	IN	B-PP
O	999	1002	the	the	DT	B-NP
O	1003	1011	protease	protease	NN	I-NP
O	1012	1022	inhibitors	inhibitor	NNS	I-NP
O	1022	1023	,	,	,	O
O	1024	1028	only	only	RB	B-NP
O	1029	1032	two	two	CD	I-NP
O	1032	1033	,	,	,	I-NP
O	1034	1042	diprotin	diprotin	NN	I-NP
O	1042	1043	-	-	HYPH	I-NP
O	1043	1044	A	A	NN	I-NP
O	1045	1048	and	and	CC	I-NP
O	1049	1069	phenylmethylsulfonyl	phenylmethylsulfonyl	NN	I-NP
O	1070	1078	fluoride	fluoride	NN	I-NP
O	1079	1080	(	(	(	O
O	1080	1084	PMSA	PMSA	NN	B-NP
O	1084	1085	)	)	)	O
O	1085	1086	,	,	,	O
O	1087	1092	could	could	MD	B-VP
O	1093	1100	inhibit	inhibit	VB	I-VP
O	1101	1106	DPPIV	DPPIV	NN	B-NP
O	1107	1115	activity	activity	NN	I-NP
O	1115	1116	.	.	.	O

O	1117	1120	The	The	DT	B-NP
O	1121	1128	present	present	JJ	I-NP
O	1129	1135	method	method	NN	I-NP
O	1136	1139	did	do	VBD	B-VP
O	1140	1143	not	not	RB	I-VP
O	1144	1153	interfere	interfere	VB	I-VP
O	1154	1158	with	with	IN	B-PP
B-Organism_substance	1159	1166	urinary	urinary	JJ	B-NP
O	1167	1178	ingredients	ingredient	NNS	I-NP
O	1179	1183	such	such	JJ	B-PP
O	1184	1186	as	as	IN	I-PP
O	1187	1197	hemoglobin	hemoglobin	NN	B-NP
O	1197	1198	.	.	.	O

O	1199	1202	The	The	DT	B-NP
O	1203	1214	correlation	correlation	NN	I-NP
O	1215	1222	between	between	IN	B-PP
O	1223	1226	the	the	DT	B-NP
O	1227	1234	present	present	JJ	I-NP
O	1235	1236	(	(	(	O
O	1236	1237	y	y	NN	B-NP
O	1237	1238	)	)	)	O
O	1239	1242	and	and	CC	O
O	1243	1255	conventional	conventional	JJ	B-NP
O	1256	1257	(	(	(	O
O	1257	1258	x	x	NN	O
O	1258	1259	)	)	)	O
O	1260	1267	methods	method	NNS	B-NP
O	1268	1270	is	be	VBZ	B-VP
O	1271	1280	presented	present	VBN	I-VP
O	1281	1283	by	by	IN	B-PP
O	1284	1287	the	the	DT	B-NP
O	1288	1296	equation	equation	NN	I-NP
O	1297	1298	y	y	NN	I-NP
O	1299	1300	=	=	SYM	B-VP
O	1301	1302	1	1	CD	B-NP
O	1302	1303	.	.	SYM	I-NP
O	1303	1307	121x	121x	CD	I-NP
O	1308	1309	+	+	SYM	I-NP
O	1310	1311	0	0	CD	I-NP
O	1311	1312	.	.	SYM	I-NP
O	1312	1315	096	096	CD	I-NP
O	1316	1317	(	(	(	O
O	1317	1318	r	r	NN	B-NP
O	1319	1320	=	=	SYM	B-VP
O	1321	1322	0	0	CD	B-NP
O	1322	1323	.	.	SYM	I-NP
O	1323	1326	993	993	CD	I-NP
O	1326	1327	)	)	)	O
O	1327	1328	.	.	.	O

O	1329	1333	Thus	Thus	RB	B-ADVP
O	1334	1337	the	the	DT	B-NP
O	1338	1345	present	present	JJ	I-NP
O	1346	1352	method	method	NN	I-NP
O	1353	1361	provides	provide	VBZ	B-VP
O	1362	1371	practical	practical	JJ	B-NP
O	1372	1382	advantages	advantage	NNS	I-NP
O	1383	1387	over	over	IN	B-PP
O	1388	1391	the	the	DT	B-NP
O	1392	1404	conventional	conventional	JJ	I-NP
O	1405	1411	method	method	NN	I-NP
O	1412	1415	for	for	IN	B-PP
O	1416	1423	routine	routine	JJ	B-NP
O	1424	1434	laboratory	laboratory	NN	I-NP
O	1435	1438	use	use	NN	I-NP
O	1438	1439	.	.	.	O

